SCHEMBL31349640

SCHEMBL31349640

Cc1nc2cc(B3OCC(C)(C)CO3)cc(F)c2n1C1CC(C)(O)C1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31349430 0.87 CCNT1 (0.32) SNCA
SCHEMBL25924390 0.87 AR (0.32) SNCA
SCHEMBL30506934 0.87 AR (0.32) SNCA
SCHEMBL25315199 0.87 AR (0.32) SNCA
SCHEMBL25319216 0.82 CYP2C9 (0.32) SNCA
SCHEMBL30506732 0.82 CYP2C9 (0.32) SNCA
SCHEMBL25924914 0.82 CYP2C9 (0.32) SNCA
SCHEMBL31349660 0.78 JAK1 (0.37)
SCHEMBL31349592 0.77 CNR2 (0.32) SNCA
SCHEMBL31349572 0.77 PRPS1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
EP-4743079-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
WO-2025015106-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed